Pyrimidine-Nitrogen Bicyclic IRAK-4 Inhibitor Compound Patent

USPTO issued patent US12590090B2 to Asahi Kasei Pharma Corporation for a novel class of pyrimidine-and nitrogen-containing bicyclic compounds functioning as IRAK-4 inhibitors. The patent lists 35 claims covering compounds represented by general formula (1) and their salts, with eight inventors including Koichiro Arai, Kenichiro Takaba, and Andrew John Potter. CPC classification falls under C07D 471/04.

This patent grant establishes intellectual property protection for Asahi Kasei Pharma's IRAK-4 inhibitor compounds, potentially blocking competitors from developing similar therapeutic candidates. Pharmaceutical companies researching IRAK-4 inhibitors for inflammatory or autoimmune disease applications should conduct freedom-to-operate analyses before advancing related programs.